This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. is a phase 3 interventional study registered as NCT07028853 by Pfizer, with 1000 participants planned, started 2025-09-28 and due to reach its primary completion in 2028-09-12. Interventions recorded: Mevrometostat, Placebo, Enzalutamide. Conditions listed: Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate. No results are recorded here; the registry entry is the source.